Morgan Stanley reiterated coverage on Imara with a new price target

1/6/22 10:34:33 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Morgan Stanley reiterated coverage of Imara with a rating of Equal-Weight and set a new price target of $4.00 from $12.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$IMRA

Date	Price Target	Rating	Analyst
1/6/2022	$12.00 → $4.00	Equal-Weight	Morgan Stanley
11/30/2021	$10.00	Buy	HC Wainwright & Co.
8/11/2021	$33.00 → $12.00	Overweight → Equal-Weight	Morgan Stanley